Replimune Group, Inc. director Kapil Dhingra filed a Form 4 on November 3, 2026, disclosing transactions on November 2, 2026, involving the exercise of a non-qualified stock option and the sale of common stock on NASDAQ:REPL.

Key Highlights

  • Option exercise: Dhingra exercised a non-qualified stock option covering 43,169 shares of common stock at an exercise price of $1.75 per share on November 2, 2026.
  • Shares sold: 21,500 shares were sold at a weighted average price of $19 per share, with individual transaction prices ranging from $18.99 to $19.03 per share.
  • Purpose of sale: According to the filing, the shares sold were "to cover tax withholding obligations in connection with the exercise of the Reporting Person's non-qualified stock option into Shares."
  • Remaining beneficial ownership: Following the transactions, Dhingra directly held 21,669 shares of common stock.
  • Option expiration: The filing states the option was exercised due to its upcoming expiration date, with the expiration date listed as January 21, 2027.
  • Option vesting: All 43,169 shares underlying the non-qualified stock option vested on January 21, 2017, according to the filing.

Dhingra's Option Exercise and Tax-Related Share Sale at Replimune Group

According to the Form 4 filed with the SEC on November 3, 2026, Kapil Dhingra, a director of Replimune Group, Inc. (NASDAQ:REPL), executed two transactions on November 2, 2026. First, he exercised a non-qualified stock option for 43,169 shares of common stock at a conversion price of $1.75 per share, using transaction code "M." The filing notes the exercise was prompted by the option's upcoming expiration date of January 21, 2027, and that all underlying shares had vested on January 21, 2017.

Following the option exercise, Dhingra sold 21,500 shares at a weighted average price of $19 per share, with sales occurring in multiple transactions at prices ranging from $18.99 to $19.03 per share. The filing specifies these shares were sold to cover tax withholding obligations arising from the option exercise. The filing further states that Dhingra will provide, upon request, information on the number of shares sold at each price within the stated range.

After both transactions, the filing reports Dhingra's direct beneficial ownership of Replimune Group common stock stood at 21,669 shares. The derivative security position, the non-qualified stock option covering 43,169 shares, was fully exercised and shows a remaining balance of zero in the filing. The Form 4 was signed by Shawn Glidden as attorney-in-fact on November 3, 2026.

What Was Disclosed

Replimune Group director Kapil Dhingra disclosed the exercise of a 43,169-share non-qualified stock option at $1.75 per share and the sale of 21,500 shares at a weighted average of $19 per share to cover tax withholding, leaving him with 21,669 shares directly held.